Search results for "Hospital"

showing 10 items of 2264 documents

Do Saharan Dust Days Carry a Risk of Hospitalization From Respiratory Diseases for Citizens of the Canary Islands (Spain)?

2021

Background: Saharan dust meets the Canary Islands at the beginning of its westward path across the North Atlantic, exceeding the European daily levels for PM10; for this reason, their two provincial capital cities, constitute optimal sites where to evaluate the health effects of this natural event. Objectives: To assess the short-term association between Saharan Dust Days (SDDs) and respiratory morbidity in the two capital cities. Methods: We carried out a time-series analysis with daily emergency hospital admissions due to all respiratory system diseases, chronic obstructive pulmonary disease (COPD) and asthma between 2001 and 2005, assessing the independent effect of SDDs, defined accordi…

Pulmonary and Respiratory MedicineSeries temporalesRespiratory diseasesSaharan dustProvincial capitalGeneralized additive modelPulmonary diseaseCalima saharianaMineral dustIngresos hospitalariosPulmonary Disease Chronic Obstructive03 medical and health sciences0302 clinical medicineAir PollutionEnvironmental healthRespiratory morbiditymedicineHumansAfrican air intrusionsRespiratory systemAsthmaHospital admissionsAir PollutantsCOPDbusiness.industryDustGeneral MedicineIntrusiones de aire africanoRespiration Disordersmedicine.diseaseModelos aditivos generalizadosAsthmaConfidence intervalPartículas en suspensiónHospitalizationEnfermedades respiratorias030228 respiratory systemSpainParticulate MatterTime-seriesbusinessParticulate matter
researchProduct

Évaluation de la pratique chirurgicale dans le traitement du cancer bronchique en France à partir de la base nationale du PMSI

2019

Background - In recent years, improving the quality of care has been a concern for health professionals in France, through the certification of institutions, accreditation and continuous professional development. Evaluation of these different measures has rarely been carried out. The objective of the study was to evaluate the quality of surgical management of lung cancer in different regions using hospital mortality as an indicator. Method - From the national database of the Program of Medical Information Systems (PMSI), data on all patients who had undergone surgery for lung cancer were extracted as well as the characteristics of the centers. The main outcome criterion was hospital mortali…

Pulmonary and Respiratory MedicineVolume d’activitésmedicine.medical_specialtyGrippe[SDV.CAN]Life Sciences [q-bio]/CancerEpidémie saisonnière03 medical and health sciences0302 clinical medicineHospital volumeBase de données nationales médico-administrative[SDV.CAN] Life Sciences [q-bio]/Cancermedicine030212 general & internal medicineChirurgieGynecologybusiness.industryRisk standardized rate of mortalityPMSI3. Good healthHospital volumeTaux standardisé de mortalité030228 respiratory systemCancer du poumonNational databaseFranceLung cancerbusinessHôpitalSurgery Medico-administrative database
researchProduct

Retrospective screening for SARS-CoV-2 among influenza-like illness hospitalizations: 2018-2019 and 2019-2020 seasons, Valencia region, Spain

2021

Este artículo se encuentra disponible en la siguiente URL: https://onlinelibrary.wiley.com/doi/epdf/10.1111/irv.12899 En este artículo de investigación también participan: Juan Mollar-Maseres, Germán Schwarz-Chavarri, Sandra García-Esteban, Joan Puig-Barberà, Javier Díez-Domingo y F. Xavier López-Labrador. On 9 March 2020, the World Health Organization (WHO) Global Influenza Programme (GIP) asked participant sites on the Global Influenza Hospital Surveillance Network (GIHSN) to contribute to data collection concerning severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We re-analysed 5833 viral RNA archived samples collected prospectively from hospital admissions for influenza-lik…

Pulmonary and Respiratory Medicinemedicine.medical_specialty2019-20 coronavirus outbreakRT‐PCRSARS-CoV-2 (Virus) - Diagnóstico - 2018-2019 - España - Valencia (Comunidad Valenciana)EpidemiologyShort CommunicationSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)PopulationShort CommunicationscoronavirusData analysis.COVID-19 - Diagnóstico - 2019-2020 - España - Valencia (Comunidad Autónoma)medicine.disease_causeWorld healthCOVID‐19Influenza HumanPandemicmedicineHumansCOVID-19 - Diagnóstico - 2018-2019 - España - Valencia (Comunidad Autónoma)Influenza - Diagnosis - 2019-2020 - Spain - Valencia (Autonomous Community)Viral rnaGripe - Diagnóstico - 2018-2019 - España - Valencia (Comunidad Autónoma)influenza‐like‐illnesseducationRetrospective StudiesCoronaviruseducation.field_of_studyInfluenza-like illnessSARS-CoV-2business.industrySARS-CoV-2 (Virus) - Diagnosis - 2018-2019 - Spain - Valencia (Autonomous Community)COVID-19 (Disease) - Diagnosis - 2019-2020 - Spain - Valencia (Autonomous Community)Public Health Environmental and Occupational HealthCOVID-19virus diseasesCOVID-19 (Disease) - Diagnosis - 2018-2019 - Spain - Valencia (Autonomous Community)Análisis de datos.HospitalizationSARS-CoV-2 (Virus) - Diagnóstico - 2019-2020 - España - Valencia (Comunidad Valenciana)Infectious DiseasesInfluenza - Diagnosis - 2018-2019 - Spain - Valencia (Autonomous Community)SpainGripe - Diagnóstico - 2019-2020 - España - Valencia (Comunidad Autónoma)Emergency medicineSARS-CoV-2 (Virus) - Diagnosis - 2019-2020 - Spain - Valencia (Autonomous Community)Seasonsbusiness
researchProduct

A review of venous thromboembolism in COVID‐19: A clinical perspective

2021

Abstract Coronavirus disease‐19 (COVID‐19) started in Wuhan, China in December 2019 and spread to all around the world in a short period of time. Hospitalized patients with COVID‐19 mostly could suffer from an abnormal coagulation activation risk with increased venous thrombosis events and a poor clinical course. The reported incidence rates of thrombotic complications in hospitalized COVID‐19 patients vary between 2.6 and 85% (both in non‐critically ill and critically ill patients). The risk of venous thromboembolism is not known in non‐hospitalized patients with COVID‐19. There are numerous studies and guidelines for administration of thromboprophylaxis for COVID‐19 cases. All hospitalize…

Pulmonary and Respiratory Medicinemedicine.medical_specialtyCoronavirus disease 2019 (COVID-19)Hospitalized patientsCritical IllnessGlobal Health03 medical and health sciences0302 clinical medicineCOVID‐19medicineHumansImmunology and AllergyGenetics(clinical)030212 general & internal medicineanticoagulationIntensive care medicinePandemicsContraindicationGenetics (clinical)Critical perspectiveSARS-CoV-2business.industryCritically illIncidenceCOVID-19Venous ThromboembolismOriginal Articlesmedicine.diseasemortalityLMWHVenous thrombosis030228 respiratory systemOriginal Articlevenous thrombosisbusinessVenous thromboembolismThrombotic complicationThe Clinical Respiratory Journal
researchProduct

Acute and sustained increase in endothelial biomarkers in COVID-19.

2020

Endothelial injury is related to poor outcomes in respiratory infections yet little is known in relation to COVID-19. Performing a longitudinal analysis (on emergency department admission and post-hospitalisation follow-up), we evaluated endothelial damage via surrogate systemic endothelial biomarkers, that is, proadrenomedullin (proADM) and proendothelin, in patients with COVID-19. Higher proADM and/or proendothelin levels at baseline were associated with the most severe episodes and intensive care unit admission when compared with ward-admitted individuals and outpatients. Elevated levels of proADM or proendothelin at day 1 were associated with in-hospital mortality. High levels maintaine…

Pulmonary and Respiratory Medicinemedicine.medical_specialtyCoronavirus disease 2019 (COVID-19)business.industryRespiratory infectionCOVID-19Emergency departmentmedicine.diseaseIntensive care unitlaw.inventionHospitalizationPneumoniaIntensive Care UnitslawDiffusing capacityInternal medicinemedicineCardiologyHumansIn patientHospital MortalityRespiratory systembusinessBiomarkersThorax
researchProduct

Assessment of the worldwide burden of critical illness: The Intensive Care Over Nations (ICON) audit

2014

Item does not contain fulltext BACKGROUND: Global epidemiological data regarding outcomes for patients in intensive care units (ICUs) are scarce, but are important in understanding the worldwide burden of critical illness. We, therefore, did an international audit of ICU patients worldwide and assessed variations between hospitals and countries in terms of ICU mortality. METHODS: 730 participating centres in 84 countries prospectively collected data on all adult (>16 years) patients admitted to their ICU between May 8 and May 18, 2012, except those admitted for fewer than 24 h for routine postoperative monitoring. Participation was voluntary. Data were collected daily for a maximum of 28 da…

Pulmonary and Respiratory Medicinemedicine.medical_specialtyCritical Illnesshealth care facilities manpower and servicesPopulationlnfectious Diseases and Global Health Radboud Institute for Molecular Life Sciences [Radboudumc 4]Critical care european intensive care icon studyComorbidityintensive care medicineGlobal HealthMOF; sepsis; critically ill[SDV.MHEP.PSR]Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tractICON Intensive CareArticleSepsisCohort StudiesOutcome Assessment (Health Care)Intensive careSepsisOutcome Assessment Health CareEpidemiologyHealth careSettore MED/41 - ANESTESIOLOGIAmedicineGlobal healthcritical illness mortalityHumansHospital MortalityeducationIntensive care medicineeducation.field_of_studyMedical Auditbusiness.industryIntensive Caremedicine.diseaseComorbidity3. Good healthIntensive Care UnitsICONbusinessCohort study
researchProduct

Treatment of heart failure with preserved ejection fraction.

2018

Heart failure, in its diverse forms based on the value of the ejection fraction, is associated to high mortality and the frequent need for hospitalization, with a consequent heavy burden on healthcare resources. For an appropriate treatment of heart failure with preserved ejection fraction (HFpEF), there are no specific drugs effective for this condition. Those indicated in HF with reduced EF (HFrEF) are of more benefit in that form of HF, according to the guidelines of the European Society of Cardiology of 2016: ACE-inhibitors, beta-blockers, anti-aldosterones are all indicated with a class of recommendation/level of evidence IA; therapy with loop diuretics is indicated in the case of clin…

Pulmonary and Respiratory Medicinemedicine.medical_specialtyEjection fractionSettore MED/09 - Medicina Internalcsh:Medicineheart failuretherapeutic strategies.Hospitalization rateInternal medicineMedicineAerobic exerciseguidelinesEjection fraction; comorbidity; guidelines; heart failure; therapeutic strategies.Ejection fractionbusiness.industryHigh mortalitylcsh:REvidence-based medicinemedicine.diseaseSettore MED/11 - Malattie Dell'Apparato CardiovascolarecomorbidityHeart failureCardiologyCardiology and Cardiovascular MedicineHeart failure with preserved ejection fractionbusinessguidelineMonaldi archives for chest disease = Archivio Monaldi per le malattie del torace
researchProduct

Defining moderate asthma exacerbations in clinical trials based on ATS/ERS joint statement

2015

Background Exacerbations are a key outcome in clinical research, providing patient-relevant information about symptomatic control, health state and disease progression. Generally considered as an episode of (sub)acute deterioration of respiratory symptoms, a precise, clinically useful definition is needed for use in clinical trials. Aim and methods Focussing on moderate exacerbations, this opinion piece reviews landmark trials and current guidelines to provide a practical definition of a moderate exacerbation. Specifically, we adapt the ATS/ERS consensus statement of terminology Reddel et al. (2009) [1] which provides a conceptual (or 'theoretical') definition for moderate exacerbations, to…

Pulmonary and Respiratory Medicinemedicine.medical_specialtyExacerbationStatement (logic)Moderate asthmaSeverity of Illness IndexAdrenal Cortex HormonesAsthma controlAdministration InhalationmedicineHumansModerate exacerbationsAnti-Asthmatic AgentsBaseline (configuration management)Randomized Controlled Trials as TopicAsthmaOperational definitionbusiness.industrymedicine.diseaseAsthmaClinical trialClinical trialClinical researchPractice Guidelines as TopicDisease ProgressionPhysical therapyEmergency Service HospitalbusinessRespiratory Medicine
researchProduct

Is an activity volume threshold really realistic for lung cancer resection?

2018

IF 1.804 (2017); International audience; Background:We analyzed volume as a continuous variable to estimate threshold, which is a methodology rarely seen in the literature. The objective of this work was to assess hospital volume for lung cancer (LC) surgery and to establish the associated threshold for acceptable in-hospital mortality (IHM). Data was obtained from the French national medico-administrative database.Methods:From January 2005 to December 2016, data from 108,571 patients operated for LC in France were collected from the national administrative database. To estimate the volume threshold, hierarchical logistic regression models were developed.Results:The crude IHM rate was 5.2% …

Pulmonary and Respiratory Medicinemedicine.medical_specialty[SDV.CAN]Life Sciences [q-bio]/Cancer030204 cardiovascular system & hematologyLung cancer (LC)Logistic regressionOddssurgery03 medical and health scienceshospital volume0302 clinical medicineHospital volumethresholdmedicineLung cancerbusiness.industryin-hospital mortality (IHM)Odds ratiomedicine.diseaseConfidence interval3. Good health030228 respiratory systemCardiothoracic surgeryEmergency medicineOriginal ArticlebusinessVolume (compression)Journal of Thoracic Disease
researchProduct

Does age over 80 years have to be a contraindication for lung cancer surgery—a nationwide database study

2018

IF 1.804 (2017); International audience; Background: Nowadays surgery remains the best treatment for localized lung cancer (LC). However, patients over 80 years old are often denied surgery because of the postoperative risk of death. This study aimed to estimate in-hospital mortality (IHM) and determine whether age over 80 is the most important predictor of IHM after LC surgery.Methods: From January 2005 to December 2015, 97,440 patients, including 4,438 patients over 80 years old, were operated on for LC and recorded in the French Administrative Database. Characteristics of patients, hospitals and surgery were analysed.Results: Crude IHM was 3.73% (n=3,639) and 7.77% (n=345) for the over 8…

Pulmonary and Respiratory Medicinemedicine.medical_specialtylobectomypredictive factors[SDV.CAN]Life Sciences [q-bio]/Cancer030230 surgery03 medical and health sciencesLiver disease0302 clinical medicinePostoperative riskmedicineLung cancerContraindicationLung cancer surgerybusiness.industryOver 80sNationwide databasein-hospital mortality (IHM)medicine.diseaseSublobar resection3. Good healthSurgeryOriginal ArticlePulmonary resectionbusinessnationwide database
researchProduct